Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

May 5, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.

Agios Reports First Quarter 2016 Financial Results

Agios Reports First Quarter 2016 Financial Results

May 5, 2016

CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the first quarter ended March 31, 2016.

Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection

Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection

May 2, 2016

Phase 2 data expected in mid-2016 New SER-109

Expanded Access Program initiated at Phase 2 clinical sites

Visterra Appoints Two Industry Leaders to its Board of Directors

Visterra Appoints Two Industry Leaders to its Board of Directors

April 21, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company, today announced the appointment of Bernadette Connaughton, Head, European Markets, Canada and Australia of Bristol-Myers Squibb, and Steven Holtzman, former Executive Vice President, Corporate Development of Biogen, to the company’s board of directors. Ms. Connaughton and Mr.

Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking

Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking

April 18, 2016

Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System. Photrexa Viscous and Photrexa are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus. Avedro’s Photrexa Viscous, Photrexa and the KXL System represent a first-in-class therapeutic treatment for this sight threatening indication.

Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti - Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia

Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti - Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia

April 20, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced that SY-1365, a first-in-class potent and selective cyclin-dependent kinase 7 (CDK7) inhibitor, was observed to induce durable tumor regression and prolong survival in in vivo models of acute myeloid leukemia (AML). These data were presented at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans. Based on the strong efficacy and safety data, Syros selected SY-1365 as its development candidate and plans to file an Investigational New Drug (IND) application with the U.S.

Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

April 18, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced that SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, was observed to inhibit the growth of cancer cells and prolong survival in in vivo models of acute myeloid leukemia (AML) with a novel RARA biomarker discovered by the Company. The biomarker was found in approximately 25 percent of AML and myelodysplastic syndrome (MDS) patient tissue samples. These data were presented at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans.

Seventh Sense Biosystems Launches Pivotal Trial For Groundbreaking TAP Diagnostic Blood Collection Device

Seventh Sense Biosystems Launches Pivotal Trial For Groundbreaking TAP Diagnostic Blood Collection Device

April 13, 2016

MEDFORD, Mass., April 13, 2016/PRNEWSWIRE/ – Seventh Sense Biosystems, a privately held health technology company developing a breakthrough painless diagnostic blood collection platform, initiated a pivotal registration trial for its TAP™ Touch Activated Phlebotomy device. The company expects to file for marketing authorization in the United States and in the European Union in the second quarter of 2016, and anticipates receiving its E.U. CE Mark and U.S. regulatory approval later this summer.

UChicago and Evelo Biosciences sign licensing deal for microbiome-based cancer immunotherapy

UChicago and Evelo Biosciences sign licensing deal for microbiome-based cancer immunotherapy

April 7, 2016

CAMBRIDGE, Mass., April 7, 2016/PRNewswire/--Evelo Biosciences and the University of Chicago announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize a microbiome-based cancer immunotherapy. The cancer therapy, developed in the laboratories of UChicago researcher Thomas Gajewski, employs select gut microbes to boost the immune system’s attack on cancer cells and improve the efficacy of anti-cancer drugs.

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

March 30, 2016

CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored by Celgene Corporation, of AG-221 or AG-120 in combination with VIDAZA® (azacitidine for injection) in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are not eligible for intensive chemotherapy.